Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:CGTX NASDAQ:NRSN NASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.63-7.4%$1.68$1.07▼$6.18$106.17M1.19941,811 shs963,920 shsCGTXCognition Therapeutics$1.29-5.1%$1.12$0.25▼$3.83$121.72M1.751.09 million shs1.10 million shsNRSNNeuroSense Therapeutics$0.75-3.8%$0.79$0.63▼$2.60$25.40M1.56101,066 shs102,135 shsPEPGPepGen$1.41-4.7%$1.80$1.01▼$7.80$102.37M1.93689,094 shs604,125 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-5.38%+0.57%+2.33%-63.33%-28.74%CGTXCognition Therapeutics-4.23%+14.29%+9.68%+32.04%+342.13%NRSNNeuroSense Therapeutics-0.04%-9.29%-17.87%-9.92%-54.11%PEPGPepGen+4.23%-1.33%-23.32%-73.94%-1.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.63-7.4%$1.68$1.07▼$6.18$106.17M1.19941,811 shs963,920 shsCGTXCognition Therapeutics$1.29-5.1%$1.12$0.25▼$3.83$121.72M1.751.09 million shs1.10 million shsNRSNNeuroSense Therapeutics$0.75-3.8%$0.79$0.63▼$2.60$25.40M1.56101,066 shs102,135 shsPEPGPepGen$1.41-4.7%$1.80$1.01▼$7.80$102.37M1.93689,094 shs604,125 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-5.38%+0.57%+2.33%-63.33%-28.74%CGTXCognition Therapeutics-4.23%+14.29%+9.68%+32.04%+342.13%NRSNNeuroSense Therapeutics-0.04%-9.29%-17.87%-9.92%-54.11%PEPGPepGen+4.23%-1.33%-23.32%-73.94%-1.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.00Hold$5.50237.42% UpsideCGTXCognition Therapeutics 2.50Moderate Buy$3.33158.40% UpsideNRSNNeuroSense Therapeutics 2.60Moderate Buy$8.501,033.18% UpsidePEPGPepGen 2.67Moderate Buy$11.60722.70% UpsideCurrent Analyst Ratings BreakdownLatest NRSN, CGTX, ALDX, and PEPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/21/2026PEPGPepGen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026ALDXAldeyra Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$5.00 ➝ $4.005/8/2026NRSNNeuroSense Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/31/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $5.003/27/2026CGTXCognition Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026CGTXCognition Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.003/25/2026NRSNNeuroSense Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.74 per shareN/ACGTXCognition TherapeuticsN/AN/AN/AN/A$0.39 per shareN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.05) per shareN/APEPGPepGenN/AN/AN/AN/A$2.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$33.85M-$0.46N/AN/AN/AN/A-57.34%-36.33%8/6/2026 (Estimated)CGTXCognition Therapeutics-$23.49M-$0.24N/AN/AN/AN/A-72.68%-53.07%8/6/2026 (Estimated)NRSNNeuroSense Therapeutics-$11.12M-$0.54N/AN/AN/AN/AN/AN/A6/22/2026 (Estimated)PEPGPepGen-$89.65M-$1.75N/AN/AN/AN/A-59.89%-49.62%8/6/2026 (Estimated)Latest NRSN, CGTX, ALDX, and PEPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/30/2026N/ANRSNNeuroSense Therapeutics-$0.1950N/AN/AN/A$0.27 millionN/A5/12/2026Q1 2026PEPGPepGen-$0.31-$0.26+$0.05-$0.26N/AN/A5/7/2026Q1 2026ALDXAldeyra Therapeutics-$0.13-$0.06+$0.07-$0.06N/AN/A5/7/2026Q1 2026CGTXCognition Therapeutics-$0.06-$0.05+$0.01-$0.05$4.40 millionN/A3/26/2026Q4 2025CGTXCognition Therapeutics-$0.06-$0.02+$0.04-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.722.72CGTXCognition TherapeuticsN/A5.925.92NRSNNeuroSense TherapeuticsN/A0.310.31PEPGPepGenN/A14.9814.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%CGTXCognition Therapeutics43.35%NRSNNeuroSense Therapeutics1.04%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics11.80%CGTXCognition Therapeutics11.11%NRSNNeuroSense Therapeutics27.40%PEPGPepGen1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1060.32 million53.20 millionOptionableCGTXCognition Therapeutics2089.50 million79.56 millionNot OptionableNRSNNeuroSense Therapeutics1032.56 million23.64 millionNot OptionablePEPGPepGen3069.17 million68.27 millionNot OptionableNRSN, CGTX, ALDX, and PEPG HeadlinesRecent News About These CompaniesPepGen, Inc. (NASDAQ:PEPG) Receives Consensus Rating of "Moderate Buy" from BrokeragesJune 3 at 3:53 AM | americanbankingnews.comPepGen (NASDAQ:PEPG) Rating Lowered to "Sell" at Wall Street ZenMay 30, 2026 | americanbankingnews.comPepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 20, 2026 | zacks.com10 Best NASDAQ Stocks Under $5 to Buy Right NowMay 18, 2026 | insidermonkey.comIs PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?May 18, 2026 | finance.yahoo.comPepGen (PEPG) Upgraded to Buy: Here's What You Should KnowMay 13, 2026 | zacks.comPepGen Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsMay 12, 2026 | businesswire.comPepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 8, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGMay 7, 2026 | prnewswire.comPepGen (PEPG) Projected to Post Earnings on ThursdayMay 7, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 28, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)April 26, 2026 | theglobeandmail.comStifel Nicolaus Sticks to Its Buy Rating for PepGen Inc. (PEPG)April 26, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 16, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 14, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 9, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 7, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRSN, CGTX, ALDX, and PEPG Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$1.63 -0.13 (-7.39%) Closing price 04:00 PM EasternExtended Trading$1.73 +0.10 (+6.26%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Cognition Therapeutics NASDAQ:CGTX$1.29 -0.07 (-5.15%) Closing price 04:00 PM EasternExtended Trading$1.36 +0.07 (+5.66%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.NeuroSense Therapeutics NASDAQ:NRSN$0.75 -0.03 (-3.85%) Closing price 04:00 PM EasternExtended Trading$0.75 0.00 (-0.01%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.PepGen NASDAQ:PEPG$1.41 -0.07 (-4.73%) Closing price 04:00 PM EasternExtended Trading$1.40 -0.01 (-0.71%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
